Neuroptix Corporation


Press Releases

April 9, 2007

Neuroptix Corp. Opens New Corporate Headquarters in Acton

Pioneer in non-invasive early detection of Alzheimer’s through laser eye scanning opens new offices in Boston suburbs

ACTON, Mass .-- Neuroptix Corporation, a Massachusetts-based pioneer in the early detection of Alzheimers disease, today announced that it has opened its corporate headquarters in Acton, Mass., as it ramps up development of its innovative technology for non-invasive diagnosis of Alzheimers disease through laser eye scanning.

Paul Hartung, President and CEO of Neuroptix, said, We are very pleased to announce expanded operations in our new facility, following our successful Series A funding and new hires of senior personnel, as we work to further develop our diagnostic platform for Alzheimers disease toward commercialization.

The new facility, leased to Neuroptix by Wedgewood Realty, is located at 20 Main Street in Acton, Mass.

About Neuroptix Corporation

Neuroptix is creating and developing an innovative, non-invasive eye test for the early diagnosis of Alzheimers Disease. Neuroptixs goal is to provide clinicians with a quick, predictive, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company collaborates with major pharmaceutical companies who use Neuroptix technology in development of new Alzheimers drugs, and with academic institutions to promote research in this area.

For more information, please visit our website at, email us at, or call us at (978) 263-0005.


#  #  #